"AI+Healthcare" Trends and the Final Outcome (Part 1)

WealthCoffee · 2026-03-24T02:22:48+00:00

Trading Week 11 of the year saw the Hong Kong market impacted by external news, with oil prices surging to reflect the importance of the East Asian economy. Amid pessimistic market expectations, healthcare stocks generally declined, with Concord Medical Services suffering significant losses, while China Cord Blood Corporation rose against the trend, indicating that some investors remain optimistic about its growth prospects.

WealthCoffee

2026-03-24 02:22:48

Abstract generation in progress

The 11th trading week of this year (March 9–15, 2026) saw the Hong Kong market heavily influenced by external news, almost following the relative negative fluctuations of oil prices alongside Japanese and other stock indices. The rapid and sharp increase in oil prices demonstrates the reliance on oil and highlights East Asia’s significant position in global manufacturing and the economy. If conflicts cannot be de-escalated in the short term, the medium-term outlook for capital markets will inevitably turn bleak. Hong Kong’s healthcare stocks also followed the trend, with HAYGIA experiencing a larger decline. On Friday, a volume-driven drop essentially announced the market’s rejection of the company’s previous efforts to “focus on cash flow and share buybacks.” All market participants are waiting for HAYGIA’s worst-ever annual report since its listing. Meanwhile, Guoshengtang diverged from the overall decline in healthcare stocks, closing higher this week, indicating that some funds still see “bargains” here and are gradually accumulating. Guoshengtang’s relatively “high growth rate” is indeed a bright spot in this year’s earnings season, though the specific figures will be revealed when the annual report is released.

We recommend accessing the Caixin database for real-time macroeconomic data, stocks, bonds, company profiles, and financial information.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.